Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting

Clinical Therapeutics

Volumn 33, Issue 4, 2011, Pages 482-497

  Asseburg, Christian ^a,b   Frank, Martin ^c   Köhne, Claus Henning ^d   Hartmann, Jörg Thomas ^e   Griebsch, Ingolf ^f   Mohr, Andrea ^f   Osowski, Ulrike ^f   Schulten, Jeltje ^f   Mittendorf, Thomas ^g  

^a Esior Oy   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d KLINIKUM OLDENBURG   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Merck Serono GmbH   (Germany)

^g Herescon GmbH   (Germany)

Author keywords

Cost effectiveness analysis; Germany; Kirsten rat sarcoma viral oncogene homolog (K ras); Liver limited disease; Metastatic colorectal cancer; Targeted therapy

Indexed keywords

BEVACIZUMAB; CALCIUMFOLINATVIPHARM; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; IRINOTECAN HOSPIRA; OXALIPLATIN; OXALIPLATIN HOSPIRA; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; FOLLOW UP; GERMANY; HEALTH INSURANCE; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; ONCOGENE K RAS; OVERALL SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; FLUOROURACIL; FOLLOW-UP STUDIES; GENES, RAS; GERMANY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MODELS, ECONOMIC; MODELS, STATISTICAL; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE;

EID: 79957645956     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.04.010     Document Type: Article

References (34)

1. Van Cutsem E., Köhne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
2. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 3:581-592.
3. iOMEDICO A.G. Tumorregister kolorektales Karzinom (TKK), 6th evaluation, data status 30 September 2009, Freiburg Accessed May 05, 2011. http://www.iomedico.org.
4. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004, 240:644-658.
5. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
6. Soto J. Health economic evaluations using decision analytic modeling. Principles and practices-utilization of a checklist to their development and appraisal. Int J Technol Assess Health Care 2002, 18:94-111.
7. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
8. Tournigand C., André T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
9. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trail of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005, 23:4866-4875.
10. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
11. Thernau T., Lumley T. Survival: survival analysis, including penalised likelihood Accessed October 11, 2010. http://r-forge.r-project.org/.
12. Van Cutsem E., Bokemeyer C., Heeger S., et al. Outcome according to metastatic site in patients with KRAS with tumors: analysis from the CRYSTAL and OPUS studies. Abstract presented at: ASCO Gastrointestinal Cancers Symposium; January 20-22 2011, San Francisco, Calif.
13. Okines A., Puerto O.D., Cunningham D., et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009, 101:1033-1038.
14. Cetuximab for the first-line treatment of metastatic colorectal cancer National Institute for Health and Clinical Excellence, Accessed October 11, 2010. http://www.nice.org.uk/nicemedia/pdf/TA176/Guidance/pdf/English.
15. Graf von der Schulenburg J.M., Greiner W., Jost F., et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008, 11:539-544. Hanover Consensus Group.
16. Schmiegel W., Pox C., Reinacher-Schick A., et al. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI, andVII). Z Gastroenterol 2010, 48:65-136.
17. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumor response and secondary respecatability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11:38-47.
18. Braun S., Prenzler A., Mittendorf T., et al. Bewertung von Ressourcenverbräuchen im deutschen Gesundheitswesen aus Sicht der Gesetzlichen Krankenversicherung. Gesundheitswesen 2009, 71:19-23.
19. Chau I., Cunningham D. Treatment in advanced colorectal cancer: what, when how?. Br J Cancer 2009, 100:1704-1719.
20. Institut für das Entgeltsystem im Krankenhaus (InEK). Fallpauschalenkatalog: G-DRG-Version 2010 Accessed May 3, 2011. http://www.g-drg.de/cms/index.php/content/download/2367/15901/version/2/file/Fallpauschalenkatalog_2010_090930.pdf.
21. Wissenschaftliches Institut der AOK (WIdO). Z-Bax: Der aktuelle DRG-Preisinddex des WIdO Accessed October 11, 2010. http://wido.de/fileadmin/wido/downloads/pdf_krankenhaus/Z-Bax/wido_kra_zbax_100712.pdf.
22. Vertrag über die Erbringung spezialisierter ambulanter Palliativversorgung (SAPV) in Nordrhein gemäβ § 132d SGB V i.V.m. § 37b SGB V Accessed October 11, 2010. http://www.ag-sapv.de/tl_files/public/mustervertraege/2009-06_Nordrhein.pdf.
23. Freier W., Rauh J., Hutzschenreuter U., et al. The pattern of metastases in colorectal cancer. Data from a clinical registry. Onkol Int J Cancer Res Treat 2010, 33(Suppl 6):175.
24. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
25. Adams R., Wilson R., Seymour M.T., et al. Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trail (MRC COIN). Eur J Cancer Suppl 2009, 7:10.
26. Tveit K.M., Guren T., Glimelius B., et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. Ann Oncol 2010, 21(Suppl 8):viii9.
27. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
28. Folprecht G., Lutz M.P., Schöffski P., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006, 17:450-456.
29. Shah S.A., Haddad R., Al-Sukhni W., et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006, 202:468-475.
30. Riquet M., Foucault C., Cazes A., et al. Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg 2010, 89:375-380.
31. Carpizo D.R., d'Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol 2009, 16:2411-2421.
32. Ciardiello F., Wohlschlegel B., Teague T., et al. Awareness and penetration of KRAS mutation testing in the treatment of patients with metastatic colorectal cancer. J Clin Oncol (Meeting Abstracts) 2010, 28(Suppl):e14074.
33. de Haas R.J., Wicherts D.A., Flores E., et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?. Ann Surg 2008, 248:626-637.
34. Robert Koch Institute and Association of Population-based Cancer Registries in Germany, eds. Cancer in Germany 2003/2004: incidence and trends Accessed October 11, 2010. http://edoc.rki.de/documents/rki_fv/reJBwqKp45PiI/PDF/24aj8tYVir1Lo_08.pdf.